Shows
Digital Health DisruptorsTop 5 Health Tech Insights You Missed in Season 1 and What’s Coming in Season 2Digital Health Disruptors is back – and with health tech advancing, Season 2 is set to deliver even bigger stories from the healthcare disruptors shaping the future. If you’re new here, catch up on Season 1 where we brought you raw, unfiltered insights from healthcare’s most forward-thinking leaders.
What we discussed
(00:00) Thank you to our listeners!
(01:10) CharmHealth's Fourth Innovation Challenge
(01:38) Gain exposure to 50,000+ clinicians
(02:06) Season 1 recap
(02:21) Getting a license to leave residency behind - Dr. Kyra Bobinet (CEO of FreshTri)
(03:48) Find a $20B market - P...
2024-11-0510 min
BiovergeDecoding Biotech: A Deep Dive into AI and Platform TechnologiesKiersten Stead, Co-Founder and Managing Partner of DCVC Bio sits down with Neil to discuss her firm’s approach to deep tech investing in biotech, her focus on platform technologies, and how to separate what’s real from what’s hype in AI
2024-01-0149 min
BiovergeFinancing Biotech: Portfolio Theory and Netflix-Inspired ModelsAndrew Lo, Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management, sits down with Neil to discuss his application of portfolio theory to address the challenges of funding drug development and how a Netflix subscription model can address the coming crisis in funding high-priced curative therapies approaching the market.
2023-12-011h 05
BiovergeBringing A Hub-and-Spoke Business Model to Regenerative MedicineFaizzan Ahmad, Co-Founder and CEO of Cure8bio, sits down with Neil to discuss its growing portfolio of regenerative medicines in development, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies.
2023-11-0144 min
BiovergeEnlisting Liquid Biopsies in the Fight Against Chronic DiseasesNathan Hunkapiller, Chief Scientific Officer and Co-Founder of Curve Biosciences, sits down with Neil to discuss liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.
2023-10-0157 min
BiovergeDeveloping Targeted Therapies to Address Heart FailureDrew Titmarsh, Co-Founder and CEO of Dynomics, sits down with Neil to discuss that lack of innovative therapies to treat heat disease, the company’s discovery platform that uses engineered cardiac organoids that function like adult human heart tissue, and how the company is using this to develop precision therapies to address the root causes of heart failure.
2023-09-0145 min
Foresight Institute RadioSonia Arrison, Longevity Mentorship | Career CounsellingSonia is a longevity investor via her company 100+ Capital, a women’s investor group called Portfolia, and advises BioVerge here in Silicon Valley. She also spends time helping the Alliance for Longevity Initiatives (A4LI). She is helping A4LI streamline the political processes for advancing longevity research and therapies. When Sonia first moved to California from Canada in 1999, she helped educate congresspeople about the internet and digital technologies. She soon became interested in nanotechnology, and by extension the Foresight Institute. Her interests then turned toward longevity, and she began writing articles here and there about the topic. Peter Th...
2023-08-1856 min
BiovergeSpeeding Drug Development by Unlocking the Mechanism of Action of Cancer TherapiesDavid Li, Co-Founder and CEO of Meliora Therapeutics, sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how Meliora's platform technology uncovers the true mechanism of action of a drug and it enables it to identify promising drug scaffolds to accelerate the development process.
2023-08-1550 min
The One Away ShowNeil Littman: Two Life-and-Death Experiences Away From Making a Bigger ImpactNeil Littman is the Founder, CEO, and Managing Director of Bioverge, a company founded on a mission to make healthcare venture capital more accessible, transparent, and affordable to a greater number of investors. Neil believes that we should all have the opportunity to invest in life-saving technologies AND have the chance to generate outsized financial returns. Neil's career spans across the healthcare industry and venture capital, holding leadership positions at Notable Labs, the California Institute for Regenerative Medicine, Thomas Weisel, and Deutsche Bank. He received a Master of Science in Biotechnology from The Johns Hopkins University, and a Bachelor...
2023-07-1358 min
BiovergeEnlisting the Viral Immune System in the Fight Against CancerAnat Burkovitz, CEO of TrojanBio, sits down with Neil to discuss its AI-drive antibodies platform, how it enlists the viral immune system in the fight against cancer, and why she thinks the technology will broaden the population of patients who will benefit from immunotherapies.
2023-06-0139 min
BiovergeBringing Precision Medicine to PsychiatryAmit Etkin, Founder and CEO of Alto Neuroscience, sits down with Neil to discuss the lack of innovation in psychiatric medicines, how the company has identified AI-derived brain biomarkers, and how that is fueling its pipeline of precision therapies to treat mental health disorders.
2023-05-2255 min
Raising HealthReengineering Healthcare and Medicine with Technology with Vineeta AgarwalaThis is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health. Together, they chat about Vineeta's dual role as a clinician and investor, the adoption curve of digital therapeutics, how Vineeta thinks about platforms and a modular, engineering-driven approach to biotech, and much more. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
2023-05-0447 min
BiovergeReengineering Healthcare and Medicine with TechnologyVineeta Agarwala, General Partner at Andreessen Horowitz's Bio + Health Fund, sits down with Neil to discuss their investment process, how technology is transforming biotech and healthcare, and why she thinks drug development is becoming more and more like software development.
2023-05-0151 min
Scaling Up Business with Bill GallagherNeil Littman — Investing in the Future of HealthThe future of health matters to every one of us. From biotech to the latest innovations, we are all impacted by the rapid transformations that are happening in healthcare. Neil is the Founder & CEO of Bioverge Ventures, an investment platform democratizing access to enable individuals to diversify their portfolio with private biotech and healthcare investments for the purposes of long-term wealth creation. Between surviving a plane crash and watching helplessly as his grandmother battled cancer, Neil realized that biotechnology was the perfect way to create more tools for more doctors to help more p...
2023-04-2641 min
BiovergeUnlocking the Potential of Genetic MedicinesDavid Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.
2023-04-1557 min
BiovergeMaking Medcines Affordable for EveryonePeter Kolchinsky, Founder and Managing Director of RA Capital Management and Founder of the nonprofit No Patient Left Behind, sits down with Neil to discuss his book “The Great American Drug Deal,” policy fights over pricing, and his organization’s efforts to make medicines affordable for all Americans.
2023-04-011h 04
BiovergeUnleashing the Power of Gene Therapy for a Broad Universe of DiseasesKriya Therapeutics Co-Founder, Chairman, and CEO Shankar Ramaswamy sits down with Neil. He discusses how the company is changing the way gene therapies are designed, developed, and manufactured in an effort to cut costs, accelerate the time to market, and expand the reach of gene therapies to a broad universe of disease.
2023-03-1553 min
BiovergeA Bioinformatician Turned Investor Seeks to Transform Drug Development with TechnologyFrancisco Gimenez, a member of the 8VC investment team, sits down with Neil to discuss how his background in data science and bioinformatics shapes his investment approach and the potential to transform drug development with technology.
2023-03-011h 04
BiovergeA Rockstar Investor Who Backs Transformational TechnologiesD.A. Wallach sits down with Neil to discuss his journey from recording artists to venture investors, his co-founding of Time BioVentures, and his vision from transforming biotechnology and healthcare with technology.
2023-02-1556 min
BiovergeHarnessing CRISPR to Cure Infectious DiseasesDaniel Dornbusch, CEO of Excision BioTherapeutics, sits down with Neil to discuss his company’s efforts to develop CRISPR-based therapies to cure HIV and other viral infectious diseases.
2023-02-0155 min
BiovergeFinding Purpose in Building Early-Stage CompaniesKhosla Ventures Partner Gwen Cheni sits down with Neil to talk her migration from Wall Street to early-stage TechBio companies, how that has shaped her investment approach in start-ups, and what emerging technologies excite her today.
2023-01-1551 min
BiovergeDeveloping Next-Generation Small Molecule DrugsRamsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s collaboration with Bristol Myers Squibb to apply its platform technologies to a set of inflammation-related pathways.
2023-01-0149 minForesight Institute RadioCareer Advice from Sonia Arrison, 100+ CapitalSonia Arrison, 100+ CapitalSonia Arrison is a longevity investor via her company 100+ Capital, a women’s investor group called Portfolia, and advises BioVerge here in Silicon Valley. She also spends time helping the Alliance for Longevity Initiatives (A4LI). She is helping A4LI streamline the political processes for advancing longevity research and therapies.When Sonia first moved to California from Canada in 1999, she helped educate congresspeople about the internet and digital technologies. She soon became interested in nanotechnology, and by extension the Foresight Institute. Her interests then turned toward longevity, and she be...
2022-12-2156 min
BiovergeThe Repurpose Driven LifeOn this episode, David Fajgenbaum, co-founder of Every Cure, sits down with Neil to discuss his new nonprofit, which is seeking to unlock the potential of already approved drugs to treat diseases for which they have not been approved. Fajgenbuam, co-founder and executive director of the Castleman Disease Collaborative Network and assistant professor of medicine at the University of Pennsylvania, recounts the story in his book Chasing My Cure and how he saved his own life by finding a drug to repurpose to treat his rare disease.
2022-12-1551 min
The Journey with Christian D EvansInvest in Early-Stage Healthcare and Biotech Companies with Neil Littman🎁 Gift for All Podcast Listeners Below 👇| I once worked in a virology lab, now I invest in early-stage healthcare and biotech companies. After receiving a Master in Science in Biotechnology from Johns Hopkins, I ventured to Wall St and started my career in healthcare investment banking where I advised biotech and healthcare companies on transactions totaling $1B.
After investment banking, I transitioned to venture philanthropy and was a member of the Executive Leadership Team at the California Institute for Regenerative Medicine (CIRM). While at CIRM, I helped develop the long-term strategic plan to manage and invest $3 billion in the r...
2022-12-0250 min
BiovergeUsing Food as Medicine to Extend Health and Treat DiseaseJoseph Antoun, CEO of L-Nutra, sits down with Neil to discuss how his company is using state-of-the art science and randomized, placebo-controlled clinical studies to use diet to extend healthy lifespans and treat a wide range of diseases.
2022-12-0156 min
BiovergeHarnessing the Many Flavors of CRISPR to Detect and Cure DiseaseTrevor Martin, co-founder of CEO of Mammoth Biosciences, sits down with Neil to discuss the power of CRISPR as a diagnostic and therapeutic tool, his company's efforts to discover new CRISPR enzymes, and how the company is building a therapeutic pipeline through partnerships and on its own.
2022-11-1556 min
Living A Life In FullNeil Littman on Bringing Science Fiction to Life and MedicineHealthcare and medicine have long served as a hotbed of innovation. Perhaps the leading edge these days requires a paradigm shift – think digital therapeutics, Web3, the metaverse, CRISPR, Software as a Medical Device – this is the domain of Neil Littman, Founder & CEO of Bioverge, a highly curated impact-investment venture platform exclusively dedicated to healthcare and to democratizing access to investing in early stage companies and startups. The Bioverge platform serves as a decentralized network linking capital to potential investment opportunities. Neil also hosts, The Bioverge Podcast. Neil talked about his time at the California Institute for Regenerative Medi...
2022-11-011h 20
BiovergeDeveloping Next-Generation in Vivo Cell and Gene TherapiesDavid Johnson, founder and CEO of GigaMune, sits down with Neil to discuss his company's efforts to develop in vivo cell and gene therapies to treat cancer and autoimmune conditions.
2022-10-171h 07
BiovergeAddressing the Challenges of Chronic Liver DiseaseJack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.
2022-06-0145 min
BiovergeEngineering Intelligence into Cell and Gene TherapiesTim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.
2022-04-0151 min
BiovergeChanging Drug Discovery with TransomicsOn this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.
2022-03-1545 min
BiovergeAccelerating Timelines and Improving Outcomes with a Predictive Precision Medicine PlatformMatt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.
2022-02-1155 min
BiovergeA Wall Street Veteran Discusses Where Biotech Has Been and What's AheadDennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.
2022-01-101h 07Foresight Institute RadioSergey Young, Neil Littman | Longevity Investing Q&AThis episode is a Q&A on longevity investing with Sergey Young from Longevity Vision Fund and Neil Littman from Bioverge.Sergey Young is a longevity investor and visionary with a mission to extend the healthy lifespans of 1 billion people. He is the founder of the $100M Longevity Vision Fund—one of the few funds specializing exclusively in longevity and helping to accelerate longevity breakthroughs.Neil J. Littman is the Founder, CEO, and General Partner at Bioverge, an impact investment platform exclusively dedicated to investing in early-stage, cutting-edge he...
2021-12-311h 01
BiovergeCuring Blindness with Cell TherapyOn this episode, Arnaud Lacoste, chief scientific officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.
2021-12-1550 min
BiovergeFrom Bugs to DrugsKareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.
2021-11-1646 min
BiovergeForging a TechBio CultureThis week Viswa Colluru, founder and CEO of Enveda Bio sits down with Neil to discuss AI in drug development, and the challenges of managing and forging a TechBio culture.
2021-10-1546 min
BiovergeInvesting in the Bio-Based FutureLindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.
2021-09-1542 min
BiovergeEvolving Failures in an Evolving Pandemic and What Needs to Be DoneEric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.
2021-08-1855 min
BiovergeBridging the Translational Science DividePete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.
2021-08-0139 min
BiovergeWhy the FDA Was Right to Approve Biogen's AduhelmJames Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.
2021-07-1542 min
BiovergeDemocratizing EntrepreneurshipJuan Scarlett, managing director of OneValley Ventures, sits down with Neil to discusses OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.
2021-07-0154 min
BiovergeManaging the Challenges of Scaling Cell and Gene TherapiesAmy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.
2021-06-1540 min
BiovergeAdvancing a Pipeline of Off-The-Shelf Cell TherapiesBrian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.
2021-06-0145 min
BiovergeWeighing the Strengths and Weakness of Various COVID-19 VaccinesCraig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.
2021-05-1455 min
BiovergeImproving Epilepsy Outcomes with Digital Health TechnologyRachel Kuperman, CEO of Eysz, sits down with Neil to discuss her company’s efforts to develop a digital health platform using passive eye-movements as input to measure, diagnose, and predict neurological disease starting with epilepsy.
2021-05-0339 min
BiovergeRemoving Toxins from Cerebrospinal Fluid to Treat Neurodegenerative DiseasesAnthony DePasqua, CEO of EnClear Therapies, sits down with Neil to discuss the company’s technology in development to remove toxic proteins from cerebrospinal spinal fluid to treat patients with ALS and other neurodegenerative conditions.
2021-04-1532 min
BiovergeDecoding the WorldArvind Gupta, founder of IndieBio and co-lead of the engineering biology practice at the venture capital firm Mayfield, and Po Bronson, author and managing director and partner at IndieBio, sit down with Neil to discuss their new book Decoding the World, IndieBio, and the future of biotech.
2021-04-0156 min
BiovergeMaking Long-Term Bets on LongevityAbout ten years ago, futurist Sonia Arrison in her book “100 Plus” explored the coming age of longevity and the broad impacts it would have. Now, as a venture investor, she’s backing companies that are positively impacting longevity through her 100 Plus Capital. In this episode, Neil talks to Arrison about the area of longevity, her investment approach, and how the field has evolved.
2021-03-1534 min
BiovergeDemocratizing HealthcareGreg Simon, former president of the Biden Cancer Initiative and former executive director of the White House Cancer Moonshot Task Force, discusses his long career in healthcare that has cut across the government, nonprofit, and private sectors. His work has extended from FasterCures, which has sought to build a patient-centric system to accelerate the development of therapies to the healthcare investment platform Poliwogg, which sought to democratize healthcare investing. Neil speaks to Greg about what he’s learned from his work, the themes that unified his career, and his own cancer diagnosis has changed his perspective
2021-03-0138 min
BiovergeShaping the Future of Regenerative MedicineIn November, voters approved a new $5.5 billion bond measure that extends the life of the California Institute for Regenerative Medicine. The measure passed with far less fanfare than the original proposition that established the institute in the midst of a national controversy over embryonic stem cell research. With the passage of the new measure, the institute is expanding its work in emerging areas of regenerative medicine including cell and gene therapies and increasing its focus on translational research and clinical development. We spoke to Jonathan Thomas, chairman of the Independent Citizens’ Oversight Committee, which oversees the California Institute for Regenerative Me...
2021-02-1052 min
Building The Future Show - Radio / TV / PodcastEpisode 307 with Neil LittmanBioverge is an investment and engagement platform that aims to connect the world to startup companies transforming healthcare.
We’re living at an exciting time - the convergence of biology and technology is rapidly driving the healthcare industry in exciting new directions – making patient care more effective, accessible, personalized, cheaper, and faster.
If you could gift the world anything, wouldn't the most impactful be the gift of better health? We believe that there is no more direct and measurable way to make an impact on people's lives than to support the future of this rapidly changing industry.
Whether by financial inve...
2018-10-2250 min
Building The Future Show - Radio / TV / PodcastEpisode 307 with Neil LittmanBioverge is an investment and engagement platform that aims to connect the world to startup companies transforming healthcare.
We’re living at an exciting time - the convergence of biology and technology is rapidly driving the healthcare industry in exciting new directions – making patient care more effective, accessible, personalized, cheaper, and faster.
If you could gift the world anything, wouldn't the most impactful be the gift of better health? We believe that there is no more direct and measurable way to make an impact on people's lives than to support the future of this rapidly changing industry.
Whether by financial inve...
2018-10-2250 min